Sanofi Pasteur MSD

Company snapshot

Sanofi Pasteur MSD maintains 83 tracked programs across Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A, Hypercholesterolemia, Dengue Fever, Asthma, Poliomyelitis, Type 2 Diabetes Mellitus, Rheumatoid Arthritis, Meningococcal infection. Momentum score: 24/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials, patents, SEC filings, a

• 83 active pipeline program(s) linked via ClinicalTrials.gov.
• 83 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sanofi Pasteur MSD. Not investment advice.

• trial_data Jun 8, 2026

  Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 40

• Peer + 0 momentum

  Boehringer Ingelheim

  TA overlap score 40

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 40

• Peer + 0 momentum

  Takeda

  TA overlap score 40

• Peer + 0 momentum

  IONIS PHARMACEUTICALS

  TA overlap score 40

• Peer + 0 momentum

  LEXICON PHARMACEUTICALS

  TA overlap score 30.2

• Peer + 0 momentum

  Hong Kong Baptist

  TA overlap score 23.6

• Peer + 0 momentum

  Oramed Pharmaceuticals

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for Sanofi Pasteur MSD.

1. Jun 8, 2026 Clinical update

   MET55 — Phase 3

2. Jun 8, 2026 Clinical update

   MEQ00074 — Phase 3

3. Jun 8, 2026 Clinical update

   CYD32 — Phase 3

4. Jun 8, 2026 Clinical update

   IPV26 — Phase 2

5. Jun 8, 2026 Clinical update

   MEQ00089 — Phase 3

View all clinical trial activity →

• What is Sanofi Pasteur MSD?

  Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clinical program(s), 0 drug profile(s), and 0 patent record(s) to

• Is Sanofi Pasteur MSD publicly traded?

  Sanofi Pasteur MSD appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sanofi Pasteur MSD develop or market?

  We link 66 drug profile(s) where Sanofi Pasteur MSD is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sanofi-pasteur#company-drugs.

• What are the latest developments for Sanofi Pasteur MSD?

  In the last 12 months our linked public records show 83 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sanofi Pasteur MSD focus on?

  Sanofi Pasteur MSD focuses on Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis based on our analysis of their pipeline programs and drug development activities.